Keywords: blows, wyeth, poi, drug, misses, ph, iii

Two blows for Wyeth: POI drug misses Ph III endpoint; withdraws desvenlafaxine MAA

Article | 24 March 2008

Print This

US drug major Wyeth and fellow USA-based Progenics Pharmaceuticals say that preliminary findings from a Phase III trial of intravenous ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in